who cares. they speak at these conferences every year and nothing comes of it. its just keeping in front of inst. investors periodically. means nothing.
another Dirk Haussecker special... notice a trend?
so if you get pneumonia and take some cough syrup and over several days your cough subsides are you "functionally cured" of pneumonia because your cough is suppressed?
the research is ongoing as to what FC looks like. If it were that simple and ARC 520 already showed effectiveness, then Locarnini would just shut down all his research and retire. there'd be nothing left to study.
its not nearly that simple. best case is knocking down S antigen has some synergistic effect on some other drug cocktail. And that data won't be complete for at least another year or longer.
there is no official definition of a functional cure. I don't know why people persist in endless debate over this. Its just the concept that the virus is being contained and its activity is at such a low level that it is no longer doing much harm.
S antigen is just one of several markers that scientists use as a measure of how active the virus is.
KD of S antigen is just part of the viral activity. certainly not the be all and end all. even HP knows this.
If a patient stops medications and the virus returns to robust activity after 6 months is the patient really 'cured'? no of course not. Some say less than 1,000 iu measure means its a cure, some don't. that's a very very low level.
whatever the data comes out I will bet ARWR changes their definition of functional cure to fit the data, and then HP will change his definition! lol.
should be easy to cure then. lol
have to realize that only a portion of population can even get this drug reimbursed. that limits # of paid scripts rmatically until more approved payors allow it tier 1 status. so the low scripts are not necessarily indication of patient or physician demand. company has said this won't change till Q3 or Q4
you are confusing symptoms with causes. the key seems to be viral load below 1,000 iu or thereabouts. even then some people can recover and others cannot. Arc 521 may help get there. or it may not. but people speculating that Locarnini's statements are hinting that they've reached seroconversion in most patients are clearly fantasy. he is not saying that. which is my point.
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative company developing anti-viral therapies and immunotherapeutics for infectious diseases like HIV/AIDS, chronic hepatitis B (CHB), chikungunya, ebola as well as an adjuvant to enhance the immune response, today announced that a futility analysis on the primary end-point of its ABX203-002 trial, a Phase IIb/III trial of ABX203 in CHB patients, determined that the trial is unlikely to reach its primary endpoint.
The ABX203-002 study is an open-label, randomized, comparative study designed to assess the efficacy of ABX203 to maintain control of the hepatitis B virus after cessation of nucleotide analogs (NUCs), in particular in controlling viral load for a much longer period of time when compared to current treatment options. This study is ongoing in seven Asian/Pacific countries (Taiwan, Hong-Kong, Thailand, Singapore, South Korea, Australia and New-Zealand). In this large scale controlled and randomized study, where 276 subjects were enrolled as of September 2015, one group of patients received ABX203 for 24 weeks, in addition to the current standard of care (nucleoside analogues, NUCs). All therapy was stopped after 24 weeks, and these patients are evaluated against a control group receiving NUCs only. The study’s primary efficacy endpoint is the percentage of subjects with viral load
getting a bit carried away. There is an element of tautology to the CP argument. If the CP involves degradation of SaG as a primary component, then of course a drug that suppresses expression of Sag is going to show that component of CP based on its methodology.
That in no way means that suppression of Sag alone is going to lead to immune clearance of teh disease. I would hope everyone here by now realizes this HBV is a complicated beast. So complex that the phd's studying it can't predict what cures it. And even when seroclearance does take place, sometimes it reemerges later. ANd often the viral replication still occurs at a low level.
Sag reduction is a symptom of lower viral load. But what level of viral replication reduction is really needed to allow immune clearance? no one knows! and for how long? no one knows!
All yu have is the data from prior TDF studies showing when someone clears the disease all these markers improve. And we understand that reducing Sag to some level helps remove receptor blocking mechanism that MAY allow immune recovery. lots and lots of unanswered questions.
hasn't that always been true? not sure what the new info is there. Arc 520 does not control the virus and its products completely as we've seen, which is why they created the open combo studies.
the CP was from prior studies. An effort to data mine for a pattern. The question is whether Sag decline was a cause or an effect of immune response.
sweet, hope they talk about their success with TKM-Ebola. LOL. another great 'knockdown' success that didn't cure anything
well, if you're holding a functional loss in this debacle there's not much else to do but search for hope in the wreckage. maybe the virion will lead to another really interesting journal article that can be monetized for $24.95 each
those were statements quoted from AZN in media. couple industry news orgs wrote articles. google